公开(公告)号：US20240350632A1

公开(公告)日：2024-10-24

申请号：US18520972

申请日：2023-11-28

Applicant: iCell Gene Therapeutics Inc.

Inventor： Yupo MA ,  Kevin PINZ ,  Masayuki WADA

IPC: A61K39/00 ,  A61P37/06

CPC classification number: A61K39/464412 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/464411 ,  A61P37/06 ,  A61K2239/21 ,  A61K2239/22

Abstract: The present invention relates to the treatment or management of autoimmune disorders, organ rejection and cancers utilizing CAR constructs that bind to T-cell surface antigens or B-cell or plasma surface antigens or both.

公开(公告)号：US20240325442A1

公开(公告)日：2024-10-03

申请号：US18288782

申请日：2022-04-29

Applicant: West China Hospital of Sichuan University

Inventor： Hanshuo YANG ,  Qiqi LI

IPC: A61K35/17 ,  A61K9/00 ,  A61K39/00 ,  A61P35/00 ,  C07K14/535 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/86

CPC classification number: A61K35/17 ,  A61K9/0019 ,  A61K39/4611 ,  A61K39/464406 ,  A61P35/00 ,  C07K14/535 ,  C07K14/7051 ,  C12N5/0636 ,  C12N15/86 ,  A61K2239/15 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/57 ,  A61K2239/59 ,  C07K2319/03 ,  C12N2740/15043

Abstract: The present invention relates to the field of bioengineering, and in particular to a chimeric antigen receptor (CAR) expression vector and use thereof. The CAR expression vector comprising a polynucleotide encoding a CAR and full length or fragment of a polynucleotide encoding a granulocyte-macrophage colony-stimulating factor (GM-CSF). The CAR-GM-T cell constructed by the present invention is capable of expressing high-level GM-CSF, not only directly enhancing killing activity of the CAR-GM-T cell per se but also facilitating the infiltration of the CAR-GM-T cell into a solid tumor. The CAR-GM-T cell has a stronger immune modulation function compared to the conventional CAR-T cell and systematically triggers the endogenous anti-tumor immune response, thereby achieving superior therapeutic efficacy against a solid tumor.

公开(公告)号：US20240277844A1

公开(公告)日：2024-08-22

申请号：US18444273

申请日：2024-02-16

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Nicolin Bloch ,  Erica Ullman ,  Aynur Hermann ,  William Olson ,  George D. Yancopoulos

IPC: A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC classification number: A61K39/4631 ,  A61K39/4613 ,  A61K39/464429 ,  C07K14/7051 ,  C07K16/283 ,  C12N5/0646 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22 ,  C07K2317/565 ,  C07K2317/622 ,  C12N2510/00

Abstract: In certain aspects, provided herein are compositions and methods for treating cancer. The methods of the present disclosure comprise administering to a subject in need thereof a NK cell expressing a CAR in combination with an antigen-binding molecule that binds to a tumor antigen, wherein the CAR-NK cell targets tumor cells through binding to the antigen-binding molecule.

公开(公告)号：US20240207316A1

公开(公告)日：2024-06-27

申请号：US18516502

申请日：2023-11-21

Applicant: ALLIFE MEDICINE (BEIJING) LIMITED

Inventor： Lida WU ,  Yuchun GU

IPC: A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/86

CPC classification number: A61K35/17 ,  A61K39/001111 ,  A61K39/4613 ,  A61K39/4631 ,  A61K45/06 ,  A61P35/00 ,  C07K16/283 ,  C12N5/0646 ,  C12N15/86 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/58 ,  C12N2740/15043

Abstract: The present invention belongs to the field of biological medicines, and particularly relates to a chimeric receptor for improving the killing activity of immune cells and an application thereof. Specifically, the present invention provides a fusion protein. The fusion protein comprises an extracellular part, an extracellular hinge region, a transmembrane region, and an intracellular region. Most preferably, the amino acid sequence of the fusion protein of the present invention is formed by sequentially connecting SEQ ID NO.: 1, SEQ ID NO.: 3, SEQ ID NO.: 5, SEQ ID NO.: 7, SEQ ID NO.: 9 and SEQ ID NO.: 11, and the immune cells expressing the fusion protein have strong killing activity.

公开(公告)号：US20240189358A1

公开(公告)日：2024-06-13

申请号：US18555243

申请日：2022-04-12

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES ,  SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH

Inventor： Scott W. Lowe ,  Corina Amor Vegas ,  Paul Romesser

IPC: A61K35/17 ,  A61K9/00 ,  A61K39/00 ,  A61K45/06 ,  A61P21/00 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K9/0019 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464429 ,  A61K45/06 ,  A61P21/00 ,  C07K16/2896 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/31 ,  A61K2239/46

Abstract: The present disclosure provides methods for treating Covid-related lung fibrosis or rectal cancer in a subject. Also disclosed herein are methods for delaying or mitigating the effects of aging in a subject in need thereof. The methods of the present technology comprise administering to the subject an effective amount of engineered immune cells that express a uPAR-specific chimeric antigen receptor.

公开(公告)号：US20240189351A1

公开(公告)日：2024-06-13

申请号：US18285218

申请日：2022-04-01

Applicant: The United States of America, as represented by the Secretary, Dept.of Health and Human Services

Inventor： Raj K. Puri ,  Bharatkumar H. Joshi

IPC: A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/86

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464419 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2866 ,  C12N5/0636 ,  C12N15/86 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22 ,  C12N2740/15043

Abstract: Immunotherapies, particularly chimeric antigen receptors targeting IL-13Rα2 and their use for treating cancer are provided. A single chain fragment variable (scFv) that specifically binds IL-13Rα2, chimeric antigen receptors (CARs) including the IL-13Rα2 scFv, nucleic acids encoding the CARs, vectors including the nucleic acids encoding the CARs, and immune cells expressing the CARs are provided. Also provided are methods of treating a subject with cancer, including administering to the subject an immune cell expressing an IL-13Rα2 scFv-CAR alone or in combination with other cancer therapies.

公开(公告)号：US20240148870A1

公开(公告)日：2024-05-09

申请号：US18281471

申请日：2022-03-11

Applicant: The Johns Hopkins University

Inventor： Michael S. Hwang ,  Jacqueline Douglass ,  Emily Han-Chung Hsiue ,  Kenneth W. Kinzler ,  Brian J. Mog ,  Nickolas Papadopoulos ,  Alexander H. Pearlman ,  Bert Vogelstein ,  Shibin Zhou

IPC: A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

CPC classification number: A61K39/464412 ,  A61K39/4611 ,  A61K39/4631 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/2803 ,  C07K16/2833 ,  C12N5/0636 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/28 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00

Abstract: Provided herein are immune cells and methods of use, wherein the immune cells include a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular antigen binding domain that binds specifically to a first epitope; and an inhibitory chimeric antigen receptor (iCAR), wherein the iCAR comprises an extracellular antigen binding domain that binds specifically to a second epitope, wherein the immune cell is activated when the immune cells binds to the first epitope and does not bind to the second epitope; and wherein the immune cell is inactivated when the immune cell binds to the first and second epitopes.

公开(公告)号：US20240148785A1

公开(公告)日：2024-05-09

申请号：US18500556

申请日：2023-11-02

Applicant: Myeloid Therapeutics, Inc.

Inventor： Daniel GETTS ,  Patrick Mendes TAVARES

IPC: A61K35/15 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C12N5/078 ,  C12N15/85

CPC classification number: A61K35/15 ,  A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464429 ,  A61P35/00 ,  C07K14/70596 ,  C12N5/0634 ,  C12N15/85 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/30

Abstract: The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

公开(公告)号：US20240131065A1

公开(公告)日：2024-04-25

申请号：US18278495

申请日：2022-02-25

Applicant: CRAGE MEDICAL CO., LIMITED

Inventor： Zonghai LI ,  Zhimin SHI

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C12N9/22

CPC classification number: A61K35/17 ,  A61K39/4631 ,  A61P35/00 ,  C07K16/2851 ,  C12N9/22 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  C07K2317/55 ,  C07K2317/622 ,  C12N2310/20

Abstract: An engineered immune cell for immunotherapy, which has a relatively high persistence and/or survival rate of transplantation in a host organism, and a preparation method therefor.

公开(公告)号：US20240108653A1

公开(公告)日：2024-04-04

申请号：US18275921

申请日：2022-02-04

Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION

Inventor： Djordje Atanackovic ,  Tim Luetkens ,  Erin Morales

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61P35/00 ,  C07K14/705 ,  C07K16/2803 ,  A61K2239/15 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/28 ,  A61K2239/46

Abstract: Disclosed are CAR polypeptides comprising a target specific receptor and a death domain. Disclosed are CAR polypeptides comprising a LINGO1 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Disclosed are CAR cells comprising one or more of the disclosed CAR polypeptides. Disclosed are cells comprising an altered α4β1 integrin. Disclosed are methods of treating comprising administering one or more of the disclosed cells to a subject in need thereof.